Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA

Lara E Sucheston-Campbell | Lara E. Sucheston-Campbell | A. Whittemore | L. Kiemeney | M. Pike | M. Beckmann | P. Fasching | R. Vierkant | T. Sellers | A. Hein | J. Chang-Claude | M. García-Closas | B. Fridley | E. Goode | Robert Brown | B. Karlan | N. Le | A. Berchuck | E. Iversen | G. Giles | G. Severi | T. Dörk | M. Southey | D. Easton | Xifeng Wu | P. Pharoah | D. Lambrechts | K. Swenerton | A. Brooks-Wilson | D. Levine | P. Hillemanns | A. Ziogas | H. Anton-Culver | U. Menon | A. Gentry-Maharaj | K. Aben | D. Eccles | G. Chenevix-Trench | L. Brinton | J. Lissowska | H. Nevanlinna | N. Bogdanova | J. Cunningham | M. Goodman | J. Dennis | E. Dicks | A. Rudolph | L. Baglietto | A. Ekici | J. Lubiński | N. Antonenkova | A. Wu | J. Tyrer | C. Bunker | S. Gayther | D. Cramer | N. Wentzensen | I. Vergote | R. Ness | S. Olson | H. Risch | L. Kelemen | S. Narod | K. Odunsi | I. Campbell | I. Runnebaum | I. Orlow | R. Weber | J. Doherty | J. Schildkraut | K. Moysich | F. Modugno | K. Lu | M. Bisogna | J. McLaughlin | H. Salvesen | L. Massuger | E. Bandera | M. Hildebrandt | M. K. Halle | C. Pearce | J. Flanagan | F. Heitz | P. Harter | R. Butzow | M. Carney | J. Lester | A. Magliocco | C. Cybulski | V. McGuire | J. Rothstein | W. Sieh | C. Walsh | M. Rossing | Honglin Song | C. Phelan | A. Jensen | S. Kjær | L. Cook | J. Gronwald | S. Tworoger | G. Lurie | R. Edwards | E. Høgdall | C. Høgdall | S. Ramus | L. Bjørge | E. Wik | J. Paul | T. Pejović | I. Rzepecka | A. Dansonka-Mieszkowska | J. Kupryjańczyk | Yi Lu | E. Despierre | L. Pelttari | P. Thompson | Yukie T. Bean | M. Dürst | S. Lambrechts | A. Leminen | Dong Liang | L. Lundvall | E. Poole | I. Schwaab | K. Terry | A. Altena | A. Study | Madalene Earp | L. Szafron | Liisa M. Pelttari | G. Friel | A. Bois | U. Chandran | O. B. O. T. C. Consortium | Australian Ovarian Cancer Study Group | Grace Friel | T. Pejovic | K. Lu | R. P. Weber

[1]  田原 康玄,et al.  生活習慣病とgenome-wide association study , 2015 .

[2]  Benjamin J. Raphael,et al.  The Mutational Landscape of Adenoid Cystic Carcinoma , 2013, Nature Genetics.

[3]  Wei Lu,et al.  Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer , 2013, Nature Genetics.

[4]  Brooke L. Fridley,et al.  GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer , 2013, Nature Genetics.

[5]  Sebastian M. Armasu,et al.  Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer , 2013, Nature Communications.

[6]  A. Whittemore,et al.  Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31 , 2013, Nature Communications.

[7]  A. Whittemore,et al.  Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case–control studies , 2013, Cancer Causes & Control.

[8]  M. Sherman,et al.  Agreement for tumor grade of ovarian carcinoma: analysis of archival tissues from the surveillance, epidemiology, and end results residual tissue repository , 2013, Cancer Causes & Control.

[9]  Joanne P Young,et al.  KRAS mutations in ovarian low-grade endometrioid adenocarcinoma: association with concurrent endometriosis. , 2012, Human pathology.

[10]  M. Pike,et al.  Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies , 2012, The Lancet. Oncology.

[11]  Angela Brooks-Wilson,et al.  Estimates of array and pool-construction variance for planning efficient DNA-pooling genome wide association studies , 2011, BMC Medical Genomics.

[12]  M. Köbel,et al.  Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. , 2011, The Lancet. Oncology.

[13]  Kenneth P. Nephew,et al.  Rethinking ovarian cancer: recommendations for improving outcomes , 2011, Nature Reviews Cancer.

[14]  S. Gygi,et al.  Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling , 2011, Science.

[15]  S. Leung,et al.  Calculator for ovarian carcinoma subtype prediction , 2011, Modern Pathology.

[16]  D. Sabatini,et al.  The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling , 2011, Science.

[17]  M. Post.  Diagnosis of Ovarian Carcinoma Cell Type is Highly Reproducible: A Transcanadian Study , 2011 .

[18]  N. Cherradi,et al.  A novel concept in antiangiogenic and antitumoral therapy: multitarget destabilization of short-lived mRNAs by the zinc finger protein ZFP36L1 , 2010, Oncogene.

[19]  R. Kurman,et al.  Ovarian intestinal-type mucinous borderline tumors: a nomenclature change is long overdue. , 2010, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[20]  Richard A. Moore,et al.  ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.

[21]  Tian-Li Wang,et al.  Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.

[22]  A. Whittemore,et al.  A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24 , 2010, Nature Genetics.

[23]  A. Whittemore,et al.  Common variants at 19p13 are associated with susceptibility to ovarian cancer , 2010, Nature Genetics.

[24]  Samuel Leung,et al.  Diagnosis of Ovarian Carcinoma Cell Type is Highly Reproducible: A Transcanadian Study , 2010, The American journal of surgical pathology.

[25]  M. Mendiola,et al.  Molecular characterization of ovarian cancer by gene-expression profiling. , 2010, Gynecologic oncology.

[26]  P. Pharoah,et al.  The inherited genetics of ovarian and endometrial cancer. , 2010, Current opinion in genetics & development.

[27]  B. Munz,et al.  ZFP36L1 is regulated by growth factors and cytokines in keratinocytes and influences their VEGF production , 2010, Growth factors.

[28]  L. Shulman.  Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome. , 2010, Obstetrics and gynecology clinics of North America.

[29]  Ie-Ming Shih,et al.  The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory , 2010, The American journal of surgical pathology.

[30]  C. Gilks.  Molecular Abnormalities in Ovarian Cancer Subtypes Other than High-Grade Serous Carcinoma , 2009, Journal of oncology.

[31]  Aleksandra,et al.  A Genome-Wide Association Study Identifies A New Ovarian Cancer Susceptibility Locus On 9 p 22 . 2 , 2010 .

[32]  A. Whittemore,et al.  A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2 , 2009, Nature Genetics.

[33]  C. Gilks,et al.  Ovarian carcinoma pathology and genetics: recent advances. , 2009, Human pathology.

[34]  Eran Halperin,et al.  Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma , 2009, Nature Genetics.

[35]  Jack A. Taylor,et al.  SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies , 2009, Nucleic Acids Res..

[36]  V. Velculescu,et al.  Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. , 2009, The American journal of pathology.

[37]  Ingeborg Dhooge,et al.  A genome-wide analysis identifies genetic variants in the RELN gene associated with otosclerosis. , 2009, American journal of human genetics.

[38]  D. Huntsman,et al.  A Limited Panel of Immunomarkers Can Reliably Distinguish Between Clear Cell and High-grade Serous Carcinoma of the Ovary , 2009, The American journal of surgical pathology.

[39]  A. Parwani.  Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma , 2009 .

[40]  A. Russo,et al.  Hereditary ovarian cancer. , 2009, Critical reviews in oncology/hematology.

[41]  Waibhav Tembe,et al.  Multimarker analysis and imputation of multiple platform pooling-based genome-wide association studies , 2008, Bioinform..

[42]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[43]  Nhu Le,et al.  Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. , 2008, Human pathology.

[44]  S. Leung,et al.  Mixed Ovarian Epithelial Carcinomas With Clear Cell and Serous Components are Variants of High-grade Serous Carcinoma: An Interobserver Correlative and Immunohistochemical Study of 32 Cases , 2008, The American journal of surgical pathology.

[45]  Nils Homer,et al.  Common sequence variants on 20q11.22 confer melanoma susceptibility , 2008, Nature Genetics.

[46]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[47]  Rebecca F. Halperin,et al.  Identification of the genetic basis for complex disorders by use of pooling-based genomewide single-nucleotide-polymorphism association studies. , 2007, American journal of human genetics.

[48]  J. Prat,et al.  Hereditary ovarian cancer. , 2005, Human pathology.

[49]  R. Walker,et al.  World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs , 2005 .

[50]  A. Malpica,et al.  The role of hMSH3 and hMSH6 in ovarian endometrioid carcinoma and relationship with microsatellite instability phenotype. , 2004, Oncology reports.

[51]  J. Prat,et al.  Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. , 2004, Human pathology.

[52]  R. Broaddus,et al.  Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. , 2004, Human pathology.

[53]  Peter Devilee,et al.  Pathology and Genetics of Tumours of the Breast and Female Genital Organs , 2003 .

[54]  J. E. Ford,et al.  Three new human members of the lipid transfer/lipopolysaccharide binding protein family (LT/LBP) , 2002, Immunogenetics.

[55]  P. V. van Diest,et al.  Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer , 2001, The Journal of pathology.

[56]  L. Sobin,et al.  World Health Organization classification of tumors , 2000, Cancer.

[57]  Hua,et al.  Identification of , 2000, Journal of insect physiology.

[58]  G. Chenevix-Trench,et al.  Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. , 1998, Cancer research.

[59]  H. Lynch,et al.  Hereditary ovarian cancer. Pedigree studies, Part II. , 1991, Cancer genetics and cytogenetics.

[60]  T. Smyrk,et al.  Hereditary nonpolyposis colorectal cancer--Lynch syndromes I and II. , 1988, Gastroenterology clinics of North America.

[61]  R. Elston,et al.  Hereditary nonpolyposis colorectal cancer (lynch syndromes I and II). II. Biomarker studies , 1985, Cancer.